EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications

Menatalla M. A. Mohamed, Maha M. M. I. Taha, Mohnd M. M. R. Ibrahim

ASIDE Gastroenterology · 26.02.2026 · 2 (2) · 15-25

DOI: 10.71079/aside.gi.022626448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ASIDE Gastroenterology, online erschienen am 26.02.2026. Verfasst von Menatalla M. A. Mohamed und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) has surpassed viral hepatitis as the primary driver of chronic liver disease globally. While traditionally viewed through the lens of hepatic progression, its clinical trajectory is increasingly defined by extrahepatic complications.

Objective

This narrative review evaluates MASLD as a manifestation of systemic metabolic failure, specifically analyzing its role in accelerating cardiovascular dysfunction and extrahepatic carcinogenesis—the two principal causes of mortality in this population.

Methods

A comprehensive literature synthesis was conducted from 2020 to December 2025, using databases including PubMed, Scopus, and the Egyptian Knowledge Bank (EKB) to identify high-impact studies and international guidelines.

Results

The pathophysiology involves a metabolic cascade whereby hepatic lipid accumulation and insulin resistance trigger systemic inflammatory signaling. Disrupted lipid handling and genetic determinants promote pro-atherogenic and pro-oncogenic environments. The review advocates a transition to risk-stratified approaches using noninvasive biomarkers, such as the FIB-4 index.

Conclusion

Addressing the bidirectional relationship between hepatic steatosis and systemic comorbidities requires a multidisciplinary therapeutic strategy. This framework provides a basis for early intervention to reduce the burden of cardiovascular events and malignancy among patients with MASLD.

Zitieren

APA

Mohamed, M. M. A., Taha, M. M. M. I., & Ibrahim, M. M. M. R. (2026). Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications. ASIDE Gastroenterology, 2(2), 15-25. https://doi.org/10.71079/aside.gi.022626448

Vancouver

Mohamed MMA, Taha MMMI, Ibrahim MMMR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications. ASIDE Gastroenterology. 2026;2(2):15-25. doi:10.71079/aside.gi.022626448

BibTeX
@article{Mohamed2026,
  author = {Mohamed, Menatalla M. A. and Taha, Maha M. M. I. and Ibrahim, Mohnd M. M. R.},
  title = {Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications},
  journal = {ASIDE Gastroenterology},
  year = {2026},
  volume = {2},
  number = {2},
  pages = {15--25},
  doi = {10.71079/aside.gi.022626448}
}
Kostenlos starten →